Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma
作者: Xin GaoOpeyemi JegedeConnor GrayPaul J. CatalanoJesse NovakDavid J. KwiatkowskiRana R. McKayDaniel J. GeorgeToni K. ChoueiriDavid F. McDermottSabina SignorettiRupal S. Bhatt
作者单位: 1Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
2Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
4Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA
5Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
6Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
7Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University School of Medicine, Durham, NC
刊名: Clinical Genitourinary Cancer, 2018
来源数据库: Elsevier Journal
DOI: 10.1016/j.clgc.2018.04.001
关键词: Metastatic kidney cancerMTORNext-generation sequencingTargeted therapy
英文摘要: Abstract(#br)Introduction(#br)Genomic events leading to activation of mechanistic target of rapamycin (mTOR) are common in renal cell carcinoma (RCC). Everolimus is an allosteric mTOR inhibitor with efficacy in metastatic RCC. We characterized the genomic profile of RCC tumors from metastatic sites and assessed whether particular alterations correlate with clinical response to everolimus.(#br)Patients and Methods(#br)An open-label, single-arm phase 2 biomarker study of everolimus 10 mg daily was conducted in metastatic RCC patients. Needle biopsy or metastasectomy was performed on metastatic tumors before everolimus initiation. Next-generation sequencing was performed using a targeted hybrid capture panel detecting alterations within exons and key introns of ≥ 300 cancer-associated genes....
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:
影响因子:1.429 (2012)

×